Elevated Preoperative Carcinoembryonic Antigen (CEA) and Ki67 Is Predictor of Decreased Survival in IIA Stage Colon Cancer

被引:61
作者
Peng, Yifan [1 ,2 ]
Wang, Lin [1 ,2 ]
Gu, Jin [1 ,2 ]
机构
[1] Beijing Canc Hosp, Peking Univ Canc Hosp Inst, Dept Colorectal Surg, Key Lab Carcinogenesis & Translat Res Minist Educ, Beijing, Peoples R China
[2] Peking Univ, Canc Hosp & Inst, Beijing Canc Hosp,Minist Educ, Dept Colorectal Surg,Key Lab Carcinogenesis & Tra, Beijing 100871, Peoples R China
关键词
INDEPENDENT PROGNOSTIC-FACTOR; COLORECTAL-CANCER; ADJUVANT CHEMOTHERAPY; THYMIDYLATE SYNTHASE; CURATIVE RESECTION; HIGH-RISK; DUKES-B; EXPRESSION; MARKERS; LEVEL;
D O I
10.1007/s00268-012-1814-7
中图分类号
R61 [外科手术学];
学科分类号
摘要
The present study was designed to investigate the prognostic factors of stage IIA (pT3N0M0) colon cancer. We retrospectively reviewed consecutive patients with stage IIA colon cancer treated with curative surgery alone from January 2004 to June 2008 in Peking University Cancer Hospital. Patient demographics, and clinical, histopathologic, and laboratory data were analyzed. Univariate and multivariate analyses were carried out to identify prognostic factors associated with 3-year disease-free survival (DFS). For the 84 valid cases reviewed in this study, the 3-year DFS was 88.1 %. That for a group with elevated CEA was 77.1 % and for a group with a normal CEA level, it was 95.9 %, with statistical difference (p = 0.007). Multivariate analysis demonstrated that CEA level (p = 0.012, OR = 8.013, 1.573-40.817), expression of Ki67 (p = 0.099, OR = 3.298, 0.799-3.610), male gender (p = 0.024, OR = 7.212, 1.293-40.237), and anemia (p = 0.011, OR = 6.461, 1.537-27.151) were the independent prognostic factors for 3-year DFS. Stratified analysis revealed that an elevated CEA level combined with high expression of Ki67 was associated with poorer prognosis (3-year DFS 70 %). An elevated preoperative serum level of CEA and high expression of Ki67 in tumor tissue were predictors of poor prognosis for patients with stage IIA colon cancer. These patients should therefore be considered candidates for receiving intensive surveillance. Future clinical trials using multicenter patient cohorts should be prospectively performed to evaluate whether these high-risk patients could benefit from adjuvant chemotherapy to improve prognosis.
引用
收藏
页码:208 / 213
页数:6
相关论文
共 52 条
[1]   Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer:: A national cancer institute-national surgical adjuvant breast and bowel project collaborative study [J].
Allegra, CJ ;
Paik, S ;
Colangelo, LH ;
Parr, AL ;
Kirsch, I ;
Kim, G ;
Klein, P ;
Johnston, PG ;
Wolmark, N ;
Wieand, HS .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (02) :241-250
[2]  
American Joint Committee on Cancer, 2017, AJCC Cancer Staging Manual, V8th
[3]   Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial [J].
Andre, Thierry ;
Boni, Corrado ;
Navarro, Matilde ;
Tabernero, Josep ;
Hickish, Tamas ;
Topham, Clare ;
Bonetti, Andrea ;
Clingan, Philip ;
Bridgewater, John ;
Rivera, Fernando ;
de Gramont, Aimery .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (19) :3109-3116
[4]  
[Anonymous], 2010, AJCC Cancer Staging Handbook, V7
[5]   Transcriptional activation of integrin β6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma [J].
Bates, RC ;
Bellovin, DI ;
Brown, C ;
Maynard, E ;
Wu, BY ;
Kawakatsu, H ;
Sheppard, D ;
Oettgen, P ;
Mercurio, AM .
JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (02) :339-347
[6]   American society of clinical oncology recommendations on adjuvant chemotherapy for stage II colon cancer [J].
Benson, AB ;
Schrag, D ;
Somerfield, MR ;
Cohen, AM ;
Figueredo, AT ;
Flynn, PJ ;
Krzyzanowska, MK ;
Maroun, J ;
McAllister, P ;
Van Cutsem, E ;
Brouwers, M ;
Charette, M ;
Haller, DG .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (16) :3408-3419
[7]  
Betge J, 2011, CANCER, V118, P2184
[8]   Identifying patients with T3-T4 node-negative colon cancer at high risk of recurrence [J].
Burdy, G ;
Panis, Y ;
Alves, A ;
Nemeth, J ;
Lavergne-Slove, A ;
Valleur, P .
DISEASES OF THE COLON & RECTUM, 2001, 44 (11) :1682-1688
[9]   CARCINOEMBRYONIC ANTIGEN [J].
BURGESS, RE .
ANNALS OF INTERNAL MEDICINE, 1986, 104 (06) :888-888
[10]  
Caro JJ, 2001, CANCER-AM CANCER SOC, V91, P2214, DOI 10.1002/1097-0142(20010615)91:12<2214::AID-CNCR1251>3.0.CO